ReviewDiabetologia2018
SGLT inhibitor adjunct therapy in type 1 diabetes.
Review in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 78 citations in OpenAlex.
- Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.Diabetes, obesity & metabolism · 2020Trial
- Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.Diabetes, obesity & metabolism · 2020Trial
- Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis.Nutrition & diabetes · 2025Article
- "Is sotagliflozin a 'wonder drug'? A review of its impact on cardiovascular, diabetic, renal, neuroprotective, and hepatic outcomes".Annals of medicine and surgery (2012) · 2025Review
- New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.Genes & diseases · 2024Review
- XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions.Cell & bioscience · 2024Article
- XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions.Research square · 2023Article
- Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.The Journal of clinical investigation · 2023Article
- Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes.Internal medicine (Tokyo, Japan) · 2023Article
- Development and optimization of amphiphilic self-assembly into nanostructured liquid crystals for transdermal delivery of an antidiabetic SGLT2 inhibitor.Drug delivery · 2022Article
- Article
- Loss of renal olfactory receptor 1393 leads to improved glucose homeostasis in a type 1 diabetic mouse model.Physiological reports · 2021Article
- Cardiovascular Risk Management in Type 1 Diabetes.Current diabetes reports · 2021Review
- The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease.Glomerular diseases · 2021Review
- Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2021Article
- Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.TouchREVIEWS in endocrinology · 2021Review
- Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report.Diabetology international · 2021Article
- The comparison of efficacy and safety between different doses of empagliflozin in insulin-treated type 1 diabetes mellitus patients: a systematic review and meta-analysis protocol.Journal of diabetes and metabolic disorders · 2020Article
- The changing face of paediatric diabetes.Diabetologia · 2020Review
- Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-insulin adjunct therapies in type 1 diabetes have been proposed as a means of improving glycaemic control and reducing risk of hypoglycaemia. Evidence to support this approach is, however, scant and few pharmacological agents have proved effective enough to become part of routine clinical care. Recent short-term Phase II trials and 24 week Phase III trials provide initial support for the use of sodium-glucose cotransporter (SGLT) inhibitors in type 1 diabetes. Two international, multicentre, randomised, controlled clinical trials, Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1) and inTandem3, have reported that SGLT inhibition with dapagliflozin and sotagliflozin, respectively, confer additional benefits in terms of a 5-6 mmol/mol (0.4-0.5%) reduction in HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.